View Information Collection Request (ICR) Package
Skip to main content
An official website of the United States government
The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Search:
Agenda
Reg Review
ICR
This script is used to control the display of information in this page.
Display additional information by clicking on the following:
All
Brief and OIRA conclusion
Abstract/Justification
Legal Statutes
Rulemaking
FR Notices/Comments
IC List
Burden
Misc.
Common Form Info.
Certification
View Information Collection (IC) List
View Supporting Statement and Other Documents
Please note that the OMB number and expiration date may not have been determined when this Information Collection Request and associated Information Collection forms were submitted to OMB. The approved OMB number and expiration date may be found by clicking on the Notice of Action link below.
View ICR - OIRA Conclusion
OMB Control No:
1018-0201
ICR Reference No:
202303-1018-006
Status:
Active
Previous ICR Reference No:
Agency/Subagency:
DOI/FWS
Agency Tracking No:
Title:
Administration of U.S. Fish and Wildlife Service Investigational New Animal Drug (INAD) Program
Type of Information Collection:
Existing collection in use without an OMB Control Number
Common Form ICR:
No
Type of Review Request:
Regular
OIRA Conclusion Action:
Approved without change
Conclusion Date:
11/14/2024
Retrieve Notice of Action (NOA)
Date Received in OIRA:
07/13/2023
Terms of Clearance:
In accordance with 5 CFR 1320, the information collection is approved for three years. In accordance with 1320.5(a), the agency is reminded that an agency cannot collect information without a valid OMB control number. As terms of clearance, the Agency is asked to please evaluate the feasibility of the data upload feature requested by a commenter.
Inventory as of this Action
Requested
Previously Approved
Expiration Date
11/30/2027
36 Months From Approved
Responses
302
0
0
Time Burden (Hours)
1,215
0
0
Cost Burden (Dollars)
289,232
0
0
Abstract:
The Aquatic Animal Drug Approval Partnership (AADAP) Program is part of the Fish and Aquatic Conservation fish health network, operating under the authority of the Federal Food, Drug, and Cosmetic Act (FDCA; 21 U.S.C. 360b(j)) which permits the use of an investigational new animal drug to generate data to support a NADA approval, is part of the Fish and Aquatic Conservation fish health network. It is the only program in the United States singularly dedicated to obtaining U. S. Food and Drug Administration (FDA) approval of new medications needed for use in fish culture and fisheries management. Ultimately, the AADAP program allows fisheries professionals to more effectively and efficiently rear and manage a variety of fish species to meet production goals, stock healthy fish, and maintain a healthy environment. In order for participants (U.S. aquaculture facilities or researchers) to be able to use an unapproved drug under AADAP’s National Investigational New Animal Drug (INAD) Program, they need to follow the FDA-approved study protocol(s) and submit the required data forms, including the INAD treatment data, to AADAP’s INAD Program. Data collection is required by the FDA under the following regulations: • 21 CFR part 511 (New Animal Drugs for Investigational Use) and • 21 CFR part 514, Subpart A (514.1 - 514.15, New Animal Drug Applications, General Provisions).
Authorizing Statute(s):
US Code:
21 USC 360b(j)
Name of Law: Federal Food, Drug, and Cosmetic Act
Citations for New Statutory Requirements:
None
Associated Rulemaking Information
RIN:
Stage of Rulemaking:
Federal Register Citation:
Date:
Not associated with rulemaking
Federal Register Notices & Comments
60-day Notice:
Federal Register Citation:
Citation Date:
86 FR 38349
07/20/2021
30-day Notice:
Federal Register Citation:
Citation Date:
88 FR 44820
07/13/2023
Did the Agency receive public comments on this ICR?
No
Number of Information Collection (IC) in this ICR:
40
IC Title
Form No.
Form Name
17α–methyltestosterone INAD #11–236 - Government
MT- (W, 1 2, 2A, 3, 4A)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR THE USE OF 17-ALPHA METHYLTESTOSTERONE IN TILAPIA (INAD #11-236)
17α–methyltestosterone INAD #11–236 - Private Sector
MT- (W, 1 2, 2A, 3, 4A)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR THE USE OF 17-ALPHA METHYLTESTOSTERONE IN TILAPIA (INAD #11-236)
17α–methyltestosterone INAD #8557 - Government
MT- (W, 1 2, 2A, 3, 4A)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR THE USE OF 17-ALPHA METHYLTESTOSTERONE IN RAINBOW TROUT AND ATLANTIC SALMON (INAD #8557)
17α–methyltestosterone INAD #8557 - Private Sector
MT- (W, 1 2, 2A, 3, 4A)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR THE USE OF 17-ALPHA METHYLTESTOSTERONE IN RAINBOW TROUT AND ATLANTIC SALMON (INAD #8557)
17β–Estradiol INAD #12–671 - Government
17BE2- (W, 1, 2, 2A, 3, 4A)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR THE USE OF ESTRADIOL (17β-estradiol) IN BROOK TROUT (INAD #12-671)
17β–Estradiol INAD #12–671 - Private Sector
17BE2- (W, 1, 2, 2A, 3, 4A)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR THE USE OF ESTRADIOL (17β-estradiol) IN BROOK TROUT (INAD #12-671)
AQUI–S®20E INAD #11–741 - Government
AQSE- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR AQUI-S®20E (eugenol) (INAD #11-741)
AQUI–S®20E INAD #11–741 - Private Sector
AQSE- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR AQUI-S®20E (eugenol) (INAD #11-741)
BENZOAK VET® INAD #11–740 - Government
BZK- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR BENZOAK VET® (benzocaine) (INAD #11-740)
BENZOAK VET® INAD #11–740 - Private Sector
BZK- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR BENZOAK VET® (benzocaine) (INAD #11-740)
Calcein (Se–Mark®) INAD #10–987 - Government
CALC- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR CALCEIN (SE-MARK®) (INAD #10-987)
Calcein (Se–Mark®) INAD #10–987 - Private Sector
CALC- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR CALCEIN (SE-MARK®) (INAD #10-987)
Chloramine–T INAD #9321 - Government
CLT- (W, 1, 2, 3)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR CHLORAMINE-T (INAD #9321)
Chloramine–T INAD #9321 - Private Sector
CLT- (W, 1, 2, 3)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR CHLORAMINE-T (INAD #9321)
Common Carp Pituitary (CCP) INAD #8391 - Government
CCP- (W, 1, 2, 3, 4N)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR COMMON CARP PITUITARY (CCP) INAD 8391
Common Carp Pituitary (CCP) INAD #8391 - Private Sector
CCP- (W, 1, 2, 3, 4N)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR COMMON CARP PITUITARY (CCP) INAD 8391
Cooperative Agreement - Government
Cooperative Agreement - Private Sector
Diquat® INAD #10–969 - Government
DQT- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR REWARD® (DIQUAT DIBROMIDE) under INAD #10-969
Diquat® INAD #10–969 - Private Sector
DQT- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR REWARD® (DIQUAT DIBROMIDE) under INAD #10-969
Erythromycin 200 Injectable INAD #12–781 - Government
ERYMICIN- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR ERYTHROMYCIN (Erymicin 200 Injection) (INAD 12-781)
Erythromycin 200 Injectable INAD #12–781 - Private Sector
ERYMICIN- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR ERYTHROMYCIN (Erymicin 200 Injection) (INAD 12-781)
Florfenicol (Aquaflor®) INAD #10–697 - Government
FFC- (W, 1, 2a, 2b, 3)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR AQUAFLOR® (florfenicol) USE AS A FEED ADDITIVE (INAD #10-697)
Florfenicol (Aquaflor®) INAD #10–697 - Private Sector
FFC- (W, 1, 2a, 2b, 3)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR AQUAFLOR® (florfenicol) USE AS A FEED ADDITIVE (INAD #10-697)
GnRH IIa Chicken Gonadotropin – Releasing Hormone II analog INAD #13–345 - Government
GnRH IIA- (W, 1, 2, 3, 4N)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR CHICKEN GONADOTROPIN-RELEASING HORMONE II ANALOG (GnRH IIa) (INAD 13-345)
GnRH IIa Chicken Gonadotropin – Releasing Hormone II analog INAD #13–345 - Private Sector
GnRH IIA- (W, 1, 2, 3, 4N)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR CHICKEN GONADOTROPIN-RELEASING HORMONE II ANALOG (GnRH IIa) (INAD 13-345)
Hydrogen peroxide (35% Perox Aid®) INAD #11–669 - Government
H202- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR 35% PEROX AID® (HYDROGEN PEROXIDE) FOR THE CONTROL OF ECTOPARASITES (INAD #11-669)
Hydrogen peroxide (35% Perox Aid®) INAD #11–669 - Private Sector
H202- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR 35% PEROX AID® (HYDROGEN PEROXIDE) FOR THE CONTROL OF ECTOPARASITES (INAD #11-669)
Lutenizing Hormone – Releasing Hormone (LHRHa) INAD #8061 - Government
LHRHA- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR LUTEINIZING HORMONE-RELEASING HORMONE ANALOG des-Gly10,[D-Ala6]LH-RH Ethylamide (LHRHa Liquid/LHR
Lutenizing Hormone – Releasing Hormone (LHRHa) INAD #8061 - Private Sector
LHRHA- (W, 1, 2, 3)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR LUTEINIZING HORMONE-RELEASING HORMONE ANALOG des-Gly10,[D-Ala6]LH-RH Ethylamide (LHRHa Liquid/LHR
Ovaplant® Salmon Gonadotropin – Releasing Hormone analoque (sGnRHa) INAD #11–375 - Government
SGNRHA/OVAPLANT- (W, 1, 2, 3, 4N)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR SALMON GONADOTROPIN-RELEASING HORMONE ANALOGUE (sGnRHa - Ovaplant®) (INAD #11-375)
Ovaplant® Salmon Gonadotropin – Releasing Hormone analoque (sGnRHa) INAD #11–375 - Private Sector
SGNRHA/OVAPLANT- (W, 1, 2, 3, 4N)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR SALMON GONADOTROPIN-RELEASING HORMONE ANALOGUE (sGnRHa - Ovaplant®) (INAD #11-375)
Ovaplant®-L Salmon Gonadotropin – Releasing Hormone analoque (sGnRHa) INAD #13–298 - Government
OVAPLANT-L- (W, 1, 2, 3, 4N)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR SALMON GONADOTROPIN-RELEASING HORMONE ANALOGUE (sGnRHa – OVAPLANT-L) (INAD 13-298)
Ovaplant®-L Salmon Gonadotropin – Releasing Hormone analoque (sGnRHa) INAD #13–298 - Private Sector
OVAPLANT-L- (W, 1, 2, 3, 4N)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR SALMON GONADOTROPIN-RELEASING HORMONE ANALOGUE (sGnRHa – OVAPLANT-L) (INAD 13-298)
Oxytetracycline hydrochloride INAD #9033 - Government
OTIMM- (W, 1, 2, 3)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR OXYTETRACYCLINE (PENNOX 343®) FOR IMMERSION THERAPY (INAD #9033)
Oxytetracycline hydrochloride INAD #9033 - Private Sector
OTIMM- (W, 1, 2, 3)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR OXYTETRACYCLINE (PENNOX 343®) FOR IMMERSION THERAPY (INAD #9033)
Oxytetracylcine dihydrate (Terramycin® 200 for Fish) INAD #9332 - Government
OTC- (W, 1, 2A, 2B, 3A, 3B)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR OXYTETRACYCLINE (TERRAMYCIN® 200 for Fish) MEDICATED FEED (INAD #9332)
Oxytetracylcine dihydrate (Terramycin® 200 for Fish) INAD #9332 - Private Sector
OTC- (W, 1, 2A, 2B, 3A, 3B)
STUDY PROTOCOL FOR AN AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR OXYTETRACYCLINE (TERRAMYCIN® 200 for Fish) MEDICATED FEED (INAD #9332)
Slice® (Emamectin Benzoate) INAD #11–370 - Government
SLICE- (W, 1, 2A, 2B, 3, 3S)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR SLICE® (EMAMECTIN BENZOATE) (INAD #11-370)
Slice® (Emamectin Benzoate) INAD #11–370 - Private Sector
SLICE- (W, 1, 2A, 2B, 3, 3S)
STUDY PROTOCOL FOR A COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR SLICE® (EMAMECTIN BENZOATE) (INAD #11-370)
ICR Summary of Burden
Total Approved
Previously Approved
Change Due to New Statute
Change Due to Agency Discretion
Change Due to Adjustment in Estimate
Change Due to Potential Violation of the PRA
Annual Number of Responses
302
0
0
302
0
0
Annual Time Burden (Hours)
1,215
0
0
1,215
0
0
Annual Cost Burden (Dollars)
289,232
0
0
289,232
0
0
Burden increases because of Program Change due to Agency Discretion:
Yes
Burden Increase Due to:
Miscellaneous Actions
Burden decreases because of Program Change due to Agency Discretion:
No
Burden Reduction Due to:
Short Statement:
This is a request for OMB approval of a new information collection in use without a control number.
Annual Cost to Federal Government:
$339,812
Does this IC contain surveys, censuses, or employ statistical methods?
No
Does this ICR request any personally identifiable information (see
OMB Circular No. A-130
for an explanation of this term)? Please consult with your agency's privacy program when making this determination.
No
Does this ICR include a form that requires a Privacy Act Statement (see
5 U.S.C. §552a(e)(3)
)? Please consult with your agency's privacy program when making this determination.
No
Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]?
No
Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]?
No
Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)?
No
Is this ICR related to the Pandemic Response?
No
Agency Contact:
Madonna Baucum 202 354-1916 madonna_baucum@nps.gov
Common Form ICR:
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(a) It is necessary for the proper performance of agency functions;
(b) It avoids unnecessary duplication;
(c) It reduces burden on small entities;
(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;
(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;
(f) It indicates the retention periods for recordkeeping requirements;
(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.
(i) It uses effective and efficient statistical survey methodology (if applicable); and
(j) It makes appropriate use of information technology.
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
Certification Date:
07/13/2023
Something went wrong when downloading this file. If you have any questions, please send an email to risc@gsa.gov.